← All trials
NCT05170399
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2022
- Primary completion
- Aug 9, 2023
- Completion date
- Aug 16, 2024
- First posted
- Dec 28, 2021
- Last posted
- Nov 25, 2022
- Enrollment
- 500
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.